NEW YORK (360Dx) – Invivoscribe said this week that it has acquired additional contiguous space for its accredited Laboratories for Personalized Molecular Medicine — or LabPPMs — in San Diego, Japan, Germany, and China. The company also said it has bolstered its clinical diagnostic test offerings to include morphology, immunohistochemistry, flow cytometry, and multiparameter flow- and next-generation sequencing-based minimal residual disease testing.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.